Largest study finds genetic risk factors linked to fibromyalgia

A genetic deep-dive into fibromyalgia—now published in Nature Medicine—has uncovered risk factors in the largest dataset of its kind. The study points toward the nervous system’s role in why some people develop the syndrome, shifting the discussion from symptom description to measurable biological mechanisms.

Fibromyalgia is typically defined by widespread pain and tenderness, along with fatigue and problems affecting sleep, memory, and mood. Although it affects roughly 2% of the global population, the biological causes have remained difficult to pin down. This new work uses population-scale genetics to map how DNA variation contributes to susceptibility.

Researchers analyzed genetic data from more than 2.5 million adults, identifying 55,000 participants diagnosed with fibromyalgia. Using genome-wide comparisons between people with and without the condition, the team searched for DNA sequence variants that occur more frequently among those at higher risk.

Instead of a single gene, the findings show a polygenic architecture: 26 genomic regions were linked to fibromyalgia risk. Many implicated genes cluster in pathways related to brain and nerve function, consistent with a disorder involving altered pain signaling and processing.

The study’s scale matters. By drawing from 11 health research cohorts across the US, UK, Finland, Estonia, Denmark, and Iceland, the authors argue their results are robust and not driven by a small or unrepresentative sample. Their analysis involved 53 researchers across seven countries.

Co-senior author Frances Williams emphasizes that studying DNA across more than 2 million individuals provides confidence in the signals, framing fibromyalgia as a problem of pain processing rather than purely psychological distress.

Intriguingly, the strongest variant signal maps to the HTT gene, known for causing Huntington’s disease when mutated. A second highlighted signal points to the GPR52 receptor, which regulates HTT levels; because GPR52 is already explored as a possible drug target in Huntington’s disease, the work raises the prospect of repurposing insights from neurodegeneration research.

The genetic data also reveal overlap with other common conditions, including low back pain, irritable bowel syndrome, and post-traumatic stress disorder. The authors interpret this as shared nervous-system mechanisms that may explain why chronic pain syndromes frequently co-occur in families and individuals.

Importantly, genetics alone is not destiny. The study suggests that even people carrying multiple risk variants may still need additional triggers—potentially painful inflammatory or arthritic events—to develop full fibromyalgia syndrome.

Finally, the team is expanding efforts through the Chronic Pain Genomics Consortium to investigate other chronic pain disorders, starting with pelvic pain. Their goal is a broader atlas of chronic pain biology—moving from correlation toward pathways that could support future diagnostics and treatments.